JPRN-UMIN000002207尚未招募4 期
Blood pressure lowering effect of combination therapy of angiotensin receptor blocker (ARB) and Ca antagonist in patients with high risk hypertension - Therapeutic efficacy of combination therapy of angiotensin receptor blocker (ARB) and Ca antagonist to patients with high risk hypertension
Department of Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School0 个研究点目标入组 40 人开始时间: 2009年7月22日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with hypersensitive history to olmesartan medoxomil, azelnidipine, valsartan and amlodipine besilate 2. Pregnant women or women who have possibility of pregnancy 3. Patients administrated with azole antifungal drug or protease inhibitor
研究者
相似试验
尚未招募
4 期
Combination low dose blood pressure lowering treatment for patients with untreated hypertensioHypertensionACTRN12617001533381George Medicines12
已完成
不适用
Blood pressure lowering effect of one compound tablet replacement as two tablets of angiotensin 2 receptor blocker(ARB) and calcium channel blocker(CCB)the hypertensive patient who has taken ARB and CCBJPRN-UMIN000008360Department of Cardiovascular Medicine, Okayama Univesity Graduate School of Medicine, Dentistry and Pharmaceutical Sciences200
已完成
不适用
Comparison of blood pressure lowering effects of increasing dose of calcium channel blocker or adding diuretics in patients with insufficient blood pressure control with moderate dose of angiotensin receptor blocker and calcium channel blocker.HypertensionJPRN-UMIN000011328Toshio Kushiro170
尚未招募
不适用
oninvasive cardiac output monitoring to optimise therapy for patients with poorly controlled hypertension: a randomised controlled trialCardiovascular - HypertensionHypertensionACTRN12611001289909The Chinese University of Hong Kong202
已完成
4 期
Antihypertensive effect of combination therapy of telmisartan and low dose hydrochrolthiazide in hypertemnsive patientsJPRN-UMIN000000798on profit Organization LINE60